A miRNA-Peptide Fusion as a Vaccine Candidate Against the Novel Coronavirus (COVID-19). Exosomes as Potential Biomarkers of SARS-Cov-2 in Lung: After and Before Vaccination LCR_2020_b008-13

doi:10.47485/2693-2504.1005

J B & Bio Engine;

2020

DOI: 10.47485/2693-2504.1005

|View full text |Cite

A miRNA-Peptide Fusion as a Vaccine Candidate Against the Novel Coronavirus (COVID-19). Exosomes as Potential Biomarkers of SARS-Cov-2 in Lung: After and Before Vaccination LCR_2020_b008-13

Abstract: A new coronavirus named Covid-19 was reported in Wuhan, China in December 2019. The first time these cases were published they were classified as “pneumonia of unknown etiology”. The etiology of this illness is now attributed to a novel virus belonging to the coronavirus (CoV) family, COVID-19. Different from both MERS-CoV and SARS-CoV, 2019-nCoV it is the seventh member of the family of coronaviruses to infect humans. We have designed a preventive vaccine in Silico aimed to protect against Covid-19 infection … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A DNA-Peptide Fusion as a Vaccine Candidate against Breast and Ovarian Cancer Metastasis: Consequent Benefit in Certain Lung Cancers

2020

J B & Bio Engine;

View full text Add to dashboard Cite

Cancer mortality data were obtained from the WHO Mortality Database. Lung cancer, with about 85% being non-small cell lung cancer is one of the most common malignant tumors, considered the leading cause of cancer-related death in both men and women (associated with breast and ovarian cancer in metastasis). From published data, we designed a preventive vaccine in Silico aimed to protect against breast and ovarian cancer involved in metastasis for lung cancer. The largest increases are expected for melanoma; cancers of the prostate, kidney, liver, and urinary bladder in males; and the lung, breast, uterus, ovarian, and thyroid in females. Among all women, lung cancer mortality rates have surpassed those for breast cancer around the world. This reflects the decline of breast cancer mortality due to screening access and effective treatment alongside entrance of certain countries lifestyle and behavior in which smoking has become more prevalent in women. One aim of this research paper is to provide a better understanding for the potential dormant repositories of outbreaks and potential metastasis of breast and ovarian cancer and its consequents in lung cancer. In this study, we present to the cDNA-peptide fusion a more stable anti-tumoral against breast and ovarian cancer. As a cDNA target, we used primers from Her2 gene fusion with peptides from Her2 and human PARP-1 proteins. Our analysis identified 16 cloning DNA (cDNA) with theorical fusion stability (FS) value among 49.30-62.41 range and theorical Exosome Affinity (EA) (cDNA-peptide and exosome) among 62.60-77.10 range. We proposed a cDNA-peptide with theorical fusion value stability FS=50.36 Cruz and exosome affinity EA=68.02 Ro. We have named the cDNA-peptide selection as: LCR_2020_B008-55. In addition, in Silico, this cDNA-peptide also manifests partial inhibiting activity on the methylated promoter genes in lung tumors, therefore, this chimera cDNA-peptide may achieve a higher representative antitumoral activity against lung cancer disease. According to the anti-tumoral monitoring after and before vaccination using the candidate LCR_2020_B008-55, we proposed exosomes as biomarkers of lung carcinogenesis after and before vaccination. Due to the cDNA-peptides, in Silico, manifesting high affinity with exosomes, where our proposed vaccine may reach high representative activity against breast, ovarian and lung cancer in a metastasis stage, we identified this chimera with a triple antitumoral action.

show abstract

A DNA-Peptide Fusion as a Vaccine Candidate against Breast and Ovarian Cancer Metastasis: Consequent Benefit in Certain Lung Cancers

2020

J B & Bio Engine;

View full text Add to dashboard Cite

show abstract

Cannabidiol and Aloe vera Extract to Human Cells: Bioactive Molecules as a Promising Anti-Lung Cancer Drug

2023

JMCCR

View full text Add to dashboard Cite

According to World Health Organisation data, cancer is one of the most influential diseases that goes head to head with heart diseases in the ranking of causes of death, causing approximately 10 million deaths annually and accounting for 20% of all deaths. Lung cancer is a leading cause of cancer-related deaths globally for both men and women. In some pre-clinical studies in cancer cell line in vitro experiments, some results have been obtained that Aloe Vera Extract (AVE) obtained from Aloe vera plant and Cannabindiol (CBD) obtained from Cannabis sativa may have anticancer effect against cancer, but more analysis is required for the reliability of these results. In this study, the cytotoxic and apoptotic effects of AVE and CBD in human lung cancer (A549 and BEAS) cells were studied in a multifaceted manner. Diagnosis of lung cancer disease is approximately 15% in the early stage and 85% in the late stage or metastatic stage. Therefore, despite the use of targeted drugs today, the 5-year survival rate of patients can only be 5-10%. In this study, the cytotoxic and apoptotic effects of AVE and CBD on human lung cancer cells A549 and healthy normal BEAS-2B cells were studied in a versatile and comparative manner. Cytotoxic effect of AVE and CBD was evaluated by xCELLigence RTCA System and AnnexinV-FITC/PI Apoptosis Assay by Flow Cytometry. In the current investigation, we discovered that AVE and CBD might incite a relative higher ratio of cell death in lung cancer cells (A549) than in non-cancer human epithelial lung cell line BEAS-2B, which may be achieved through regulating mitochondrial metabolism. In summary, our research is under Patent submission and shows that CBD and AVE have the potential to develop into a potent new anti-lung cancer drug.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A miRNA-Peptide Fusion as a Vaccine Candidate Against the Novel Coronavirus (COVID-19). Exosomes as Potential Biomarkers of SARS-Cov-2 in Lung: After and Before Vaccination LCR_2020_b008-13

Cited by 2 publications

References 19 publications

A DNA-Peptide Fusion as a Vaccine Candidate against Breast and Ovarian Cancer Metastasis: Consequent Benefit in Certain Lung Cancers

A DNA-Peptide Fusion as a Vaccine Candidate against Breast and Ovarian Cancer Metastasis: Consequent Benefit in Certain Lung Cancers

Cannabidiol and Aloe vera Extract to Human Cells: Bioactive Molecules as a Promising Anti-Lung Cancer Drug

Contact Info

Product

Resources

About